Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ORY-1001 plus azacitidine in older adults with first-line AML
2018-000482-36Phase 2Completed
- Sponsor
- Oryzon Genomics
- Start
- Jun 2018
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of iadademstat and azacitidine in acute myeloid leukemia (AML), sponsored by Oryzon Genomics. Primary endpoints: Dose finding, Safety and 1 more. Started Jun 2018; status: completed.
02
Drugs
iadademstatazacitidine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on 2018-000482-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-000482-36.